The SPARTAN, PROSPER, and ARAMIS trials led to the FDA approval of the nonsteroidal antiandrogen agents apalutamide, enzalutamide, and darolutamide for nonmetastatic castration-resistant prostate cancer. These pivotal studies demonstrated that each of these therapies can significantly improve overall survival for patients with this disease.
In this ReCAP, Dr Nicholas J. Vogelzang, of the University of Nevada School of Medicine, discusses important similarities and differences among the studies. He compares the reduction in death rates, taking into account differences in study design, and reviews notable differences in drug toxicities.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Therapy for Nonmetastatic Castration-Resistant Prostate Cancer - Medscape - Mar 12, 2021.
Comments